Market Closed -
Nasdaq
01:30:00 29/06/2024 am IST
|
5-day change
|
1st Jan Change
|
24.35
USD
|
-0.41%
|
|
-11.29%
|
-22.77%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
164.5
|
1,122
|
975.6
|
450.4
|
842.6
|
655.8
|
-
|
-
|
Enterprise Value (EV)
1 |
164.5
|
672.7
|
668.2
|
149.4
|
576.5
|
319.5
|
655.8
|
655.8
|
P/E ratio
|
-5.06
x
|
-12.2
x
|
-4.78
x
|
48.5
x
|
-31.5
x
|
-7.24
x
|
-12.2
x
|
13.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7.92
x
|
118
x
|
78.9
x
|
2.19
x
|
4.96
x
|
3.61
x
|
2.86
x
|
1.7
x
|
EV / Revenue
|
7.92
x
|
70.5
x
|
54.1
x
|
0.73
x
|
3.39
x
|
1.76
x
|
2.86
x
|
1.7
x
|
EV / EBITDA
|
-
|
-
|
-3.31
x
|
10.9
x
|
-7.99
x
|
-3.83
x
|
-6.44
x
|
-4.04
x
|
EV / FCF
|
-
|
-1,50,81,355
x
|
-28,27,861
x
|
-
|
-
|
-
|
-48,01,192
x
|
-81,00,573
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-0%
|
-0%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
15,138
|
25,858
|
26,361
|
26,555
|
26,723
|
26,932
|
-
|
-
|
Reference price
2 |
10.87
|
43.38
|
37.01
|
16.96
|
31.53
|
24.35
|
24.35
|
24.35
|
Announcement Date
|
11/03/20
|
01/03/21
|
28/02/22
|
28/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.79
|
9.539
|
12.36
|
206
|
169.9
|
181.8
|
229.3
|
386.6
|
EBITDA
1 |
-
|
-
|
-201.7
|
13.7
|
-72.11
|
-83.39
|
-101.8
|
-162.2
|
EBIT
1 |
-25.51
|
-71.52
|
-202.9
|
12.18
|
-75.07
|
-93.73
|
-58.98
|
63.81
|
Operating Margin
|
-122.72%
|
-749.81%
|
-1,641.33%
|
5.91%
|
-44.18%
|
-51.55%
|
-25.72%
|
16.51%
|
Earnings before Tax (EBT)
1 |
-25.99
|
-72.15
|
-203.7
|
10.64
|
-24.76
|
-75.34
|
-59.29
|
46.08
|
Net income
1 |
-25.99
|
-72.15
|
-203.7
|
9.349
|
-26.59
|
-91.43
|
-60.43
|
43.47
|
Net margin
|
-125.02%
|
-756.35%
|
-1,647.98%
|
4.54%
|
-15.65%
|
-50.28%
|
-26.35%
|
11.24%
|
EPS
2 |
-2.150
|
-3.550
|
-7.740
|
0.3500
|
-1.000
|
-3.362
|
-1.989
|
1.765
|
Free Cash Flow
|
-
|
-44.6
|
-236.3
|
-
|
-
|
-
|
-136.6
|
-80.96
|
FCF margin
|
-
|
-467.59%
|
-1,911.95%
|
-
|
-
|
-
|
-59.56%
|
-20.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/20
|
01/03/21
|
28/02/22
|
28/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
5.794
|
5.244
|
27.09
|
13.37
|
160.3
|
80.28
|
10.52
|
45.14
|
33.99
|
38.01
|
22.23
|
44.3
|
69.95
|
50.59
|
58.22
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-14.32
|
-29.51
|
-38.92
|
-12.2
|
-7.653
|
-
|
-
|
EBIT
1 |
-37.64
|
-50.38
|
-22.09
|
-36.81
|
121.5
|
14.76
|
-55.37
|
-19.31
|
-15.14
|
-30.41
|
-43.92
|
-25.77
|
2.27
|
-25.93
|
-12.25
|
Operating Margin
|
-649.72%
|
-960.7%
|
-81.53%
|
-275.32%
|
75.77%
|
18.38%
|
-526.42%
|
-42.79%
|
-44.54%
|
-80.01%
|
-197.56%
|
-58.19%
|
3.25%
|
-51.26%
|
-21.05%
|
Earnings before Tax (EBT)
1 |
-38.66
|
-51.17
|
-21.56
|
-35.27
|
118.6
|
50.86
|
-51.97
|
-15.33
|
-8.311
|
-26.45
|
-44.13
|
-30.34
|
2.337
|
-26.08
|
-12.4
|
Net income
1 |
-38.66
|
-51.17
|
-21.56
|
-35.27
|
117.3
|
50.75
|
-52.55
|
-16.22
|
-8.573
|
-26.82
|
-44.18
|
-30.39
|
2.287
|
-26.08
|
-12.4
|
Net margin
|
-667.31%
|
-975.76%
|
-79.59%
|
-263.79%
|
73.21%
|
63.22%
|
-499.57%
|
-35.94%
|
-25.22%
|
-70.55%
|
-198.72%
|
-68.6%
|
3.27%
|
-51.56%
|
-21.31%
|
EPS
2 |
-1.470
|
-1.940
|
-0.8200
|
-1.330
|
4.330
|
1.870
|
-1.980
|
-0.6100
|
-0.3200
|
-1.000
|
-1.707
|
-1.006
|
0.0281
|
-0.8375
|
-0.7175
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/02/22
|
09/05/22
|
09/08/22
|
09/11/22
|
28/03/23
|
09/05/23
|
07/08/23
|
14/11/23
|
07/03/24
|
08/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
449
|
307
|
301
|
266
|
336
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-44.6
|
-236
|
-
|
-
|
-
|
-137
|
-81
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-65.2%
|
3.75%
|
-9.64%
|
-34.4%
|
-74.3%
|
-75.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.82
|
1.74
|
-
|
7.73
|
2.9
|
8
|
6.61
|
7.17
|
Capex / Sales
|
3.93%
|
18.26%
|
-
|
3.75%
|
1.71%
|
4.4%
|
2.88%
|
1.85%
|
Announcement Date
|
11/03/20
|
01/03/21
|
28/02/22
|
28/03/23
|
07/03/24
|
-
|
-
|
-
|
Last Close Price
24.35
USD Average target price
74.75
USD Spread / Average Target +206.98% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.77% | 66Cr | | +19.41% | 4.55TCr | | +38.65% | 3.81TCr | | -8.62% | 3.85TCr | | +26.95% | 3.07TCr | | -13.50% | 2.6TCr | | +10.74% | 2.59TCr | | +44.87% | 1.41TCr | | +34.36% | 1.27TCr | | -7.14% | 1.13TCr |
Other Biotechnology & Medical Research
|